Pre-Open Stock Movers 07/10: (WIMI) (MATX) (SPAQ) Higher; (ZIOP) (FC) (WDFC) Lower (more...)

July 10, 2020 9:26 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Pre-Open Stock Movers:

WIMI Hologram Cloud (NASDAQ: WIMI) 119% HIGHER; specializes in computer vision holographic cloud services. WIMI cover from the holographic AI computer vision synthesis, holographic visual presentation, holographic interactive software development and holographic AR online and offline advertising, holographic ARSDK pay, 5 g holographic communication software development, holographic face recognition and development, holographic AI in face of the development of the technology such as holographic AR multiple links, holographic cloud is a comprehensive technology solutions provider. Its business application scene is mainly gathered in five professional fields, such as home entertainment, lightfield cinema, performing arts system, commercial release system and advertising display system.

Matson, Inc. (NYSE: MATX) 25% HIGHER; announces preliminary second quarter financial results, provides a business update and announces second quarter earnings call date.

Spartan Energy Acquisition (NYSE: SPAQ) 15.7% HIGHER; adds to 39% intra-day gains on reports it is in the lead to acquire EV maker Fisker.

Greenbrier Cos. (NYSE: GBX) 12.8% HIGHER; reported Q3 EPS of $1.05, $0.91 better than the analyst estimate of $0.14. Revenue for the quarter came in at $762.6 million versus the consensus estimate of $616.06 million.

DAVIDsTEA Inc. (Nasdaq: DTEA) 11% HIGHER; announces that further to obtaining an Initial Order pursuant to the Companies’ Creditors Arrangement Act (Canada) (“CCAA”) from the Quebec Superior Court in order to implement its restructuring plan, the Company is sending notices to terminate leases for 82 of its stores in Canada and all 42 of its stores in the United States. The lease terminations will take effect in 30 days.

Ziopharm Oncology, Inc. (NASDAQ: ZIOP) 8.6% LOWER; announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing (RPM) technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center.

Franklin Covey (NYSE: FC) 8.6% LOWER; reported Q3 EPS of ($0.79), $0.49 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $37.1 million versus the consensus estimate of $48.88 million.

Simulations Plus (NASDAQ: SLP) 6.5% HIGHER; reported Q3 EPS of $0.16, $0.07 better than the analyst estimate of $0.09. Revenue for the quarter came in at $12.3 million versus the consensus estimate of $11.21 million.

PriceSmart (NASDAQ: PSMT) 5.8% HIGHER; reported Q3 EPS of $0.41, $0.15 better than the analyst estimate of $0.26. Revenue for the quarter came in at $799.93 million versus the consensus estimate of $693.45 million.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) 4.4% HIGHER; announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia. Amneal immediately initiated commercialization activities across all dosages.

WD-40 Co. (NASDAQ: WDFC) 4.2% LOWER; reported Q3 EPS of $1.06, $0.01 worse than the analyst estimate of $1.07. Revenue for the quarter came in at $98.2 million versus the consensus estimate of $108.1 million.

Beyond Meat Inc. (NASDAQ: BYND) 3% LOWER; Citi initiates coverage on with a Sell rating and a price target of $123.00.

Netflix (NASDAQ: NFLX) 2.5% HIGHER; Goldman Sachs raised the price target onto a 'Street High' $670.00 (from $540.00) while maintaining a Conviction Buy rating.

Fastly Inc. (NYSE: FSLY) 2.4% HIGHER; BofA Securities downgraded from Buy to Underperform.

Gilead Sciences Inc (NASDAQ: GILD) 2% HIGHER; additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.

Redfin Corp. (NASDAQ: RDFN) 1.9% LOWER; RBC Capital downgraded from Outperform to Sector Perform with a price target of $41.00.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Goldman Sachs Conviction Buy List, Goldman Sachs, Citi, RBC Capital, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers, FDA